Key Highlights

● Net revenues grew at a double-digit pace to about $17.4 billion.

● Adjusted Earnings guidance was raised, and the quarterly Dividend rose roughly 5%.

● The Apogee Therapeutics Acquisition closed, adding antibodies for atopic dermatitis and asthma.

● The FDA approved Skyrizi induction by injection in Crohn's disease and Juvmo for Parkinson's disease.

AbbVie (NYSE:ABBV) reported a third quarter on October thirtieth that combined fast Revenue growth, a higher full-year earnings guide and a larger quarterly dividend. Net revenues reached about $17.4 billion, up roughly 10% on both a reported and an operational basis, with immunology and neuroscience doing most of the lifting. Adjusted Diluted Earnings per Share were $3.82, while the reported figure was $2.37.

The announcement came packed with corporate news. The company said it has completed its acquisition of Apogee Therapeutics, adding two experimental antibodies aimed at atopic dermatitis and asthma, and it reported that the Food and Drug Administration approved both an injectable induction regimen of Skyrizi for Crohn's disease and Juvmo for Parkinson's disease. The board also raised the quarterly dividend by just over 5%, payable in February.

For readers who follow Dividend Stocks, AbbVie is a case study in succession planning for a blockbuster drug. Humira, once the top-grossing medicine in the world, has been eroded by biosimilars, and the new immunology pair of Skyrizi and Rinvoq has taken over as the engine.

What were the headline figures for the quarter?

Net revenues of about $17.4 billion grew by a little over 10% from a year earlier, with currency making only a slight difference. The company said revenue was roughly $200 million above its own expectations. Adjusted diluted earnings per share of $3.82 included an 11-cent charge for acquired in-process research and milestones, a type of cost AbbVie treats as part of its adjusted results.

Reported diluted earnings per share were lower, at $2.37, because the reported figure also carries amortization of intangible assets and other items that the adjusted measure excludes. Chief executive Robert Michael said the company continues to deliver outstanding results across a diverse portfolio, an assessment that the quarter's breadth of growth supports.

How are Skyrizi and Rinvoq performing against Humira?

Immunology revenue came to roughly $9.2 billion, up about 16%. Skyrizi alone contributed about $5.8 billion, and Rinvoq about $2.7 billion, each growing at a rate above 20% according to third-party summaries of the call. Humira, by contrast, fell to just over $680 million, a steep decline caused by biosimilar competition.

The combination of Skyrizi and Rinvoq is now far larger than what remains of Humira, which means the transition the company has discussed for years has effectively been completed in revenue terms. The question for the coming period is how long the two newer brands can keep growing at current rates before they too encounter Patent expiry, a question management addresses on each call.

What did the Crohn's disease approval change?

The company said the FDA approved a subcutaneous induction regimen for Skyrizi in Crohn's disease. Until now, patients starting therapy typically received an intravenous infusion, so a regimen that can begin with injections at home or in the clinic simplifies the start of treatment. A study of the approach had reported positive topline results earlier in the year.

The approval matters commercially because ease of starting therapy influences prescribing patterns and access. Management indicated on the Earnings Call that the ramp for Crohn's access would be one of the areas to watch, and the commercial chief was likely to be asked how quickly payers adopt the new regimen. The company has not given a precise sales estimate for the indication.

How did neuroscience perform and what is Juvmo?

Neuroscience revenue was about $3.4 billion, up roughly 19%. Vraylar, a treatment for psychiatric conditions, and Botox Therapeutic each contributed around $1.1 billion. The migraine pair of Ubrelvy and Qulipta added about $850 million, and Vyalev, a treatment for advanced Parkinson's disease delivered by infusion, brought in a bit under $300 million.

The newly approved Juvmo, which carries the generic name tavapadon, adds an oral Parkinson's option to that franchise. Management told listeners that the launch would ramp gradually, with broader coverage in the Medicare program not expected until later in the decade. The measured language indicates that the company is not building near-term revenue guidance on the new drug.

What happened in oncology and aesthetics?

Oncology revenue was close to flat at about $1.7 billion. Venclexta grew by a double-digit rate to about $800 million, while Imbruvica fell to about $520 million on competition and the effects of the Inflation Reduction Act pricing rules. Elahere contributed over $200 million.

Aesthetics revenue slipped by around 1% to about $1.2 billion. Botox Cosmetic grew by a few percent to about $670 million, but Juvederm declined by roughly a tenth, reflecting competition in the filler market. The company has said it expects the aesthetics Business to be roughly flat for the full year.

How was full-year guidance changed for AbbVie?

Adjusted diluted earnings per share for the year are now expected between $13.95 and $13.99, up from a prior range that started lower at $13.76 and ended at $13.96. The change moves the midpoint up by about $0.11.

Management also said it expected fourth quarter revenue and earnings within specific ranges and that full-year revenue guidance rose by about $200 million. As is its custom, the company noted that guidance excludes the effect of any acquired in-process Research and Development charges or milestone payments that have not yet been incurred.

What did the dividend decision involve?

The board raised the quarterly dividend by about 5%, from $1.73 to $1.82 per share. The new payment is scheduled for the middle of February. The increase continues a long series of annual hikes, a record that appeals to people who follow dividend payers.

The company has said in the past that its objective is to balance the dividend with Debt reduction and deals. After the Apogee closing, it told listeners that net Leverage should drop to around two times earnings over two to three years, and that later acquisitions are likely to be bolt-on additions rather than another large transaction.

What does the Apogee acquisition add?

Apogee Therapeutics is a clinical-stage company whose lead programme, zumilokibart, aims at a specific inflammation pathway called interleukin 13 in atopic dermatitis, while a second candidate, still at an early stage, is being developed for asthma. The asthma programme is identified only by an internal code. Both candidates belong to the inflammation and immunology area where AbbVie already has scale.

The company has not given revenue estimates for either programme, and both remain in clinical development. The addition fits the stated aim of extending the immunology Franchise beyond Skyrizi and Rinvoq, and it also explains part of the acquired research charge that affected the quarter.

Which pipeline events came with the report?

A Biologics license application for etentamig, a treatment for relapsed or refractory multiple myeloma, has been submitted, with a decision expected next year. Lutikizumab met its main goal in a late-stage trial in hidradenitis suppurativa, and a combination of Epkinly with the R-CHOP chemotherapy regimen reduced the chance of progression or death by about half in a late-stage lymphoma study, with regulatory filings planned early next year.

Management also said it plans to resubmit a U.S. application for a separate programme before the end of the year, with a decision possible around the middle of next year. Separately, a federal court ruled in AbbVie's favour regarding whether Botox qualifies for Medicare drug price negotiation, though the government can still appeal.

How should readers interpret adjusted versus reported earnings?

AbbVie, like most large drug makers, reports two sets of earnings figures. The reported measure follows accounting rules and includes the amortization of intangible assets acquired in earlier deals, as well as acquisition costs and other one-time items. The adjusted measure removes those items so that readers can see operating performance more clearly, although it keeps in acquired in-process research and milestone charges, which is unusual and explains the 11-cent hit mentioned in the release.

The gap between the two measures this quarter was more than a dollar per share. The size of that gap is a reminder that the company carries a large amount of acquisition-related amortization from its earlier acquisition of Allergan, and that the adjusted view is the one used for guidance and for the dividend discussion. Readers should always read both tables in the release rather than relying on the headline alone.

What does the cash position look like after the deal?

Free Cash Flow for the first nine months was about $14 billion, according to coverage of the earnings call, and cash at the end of September stood at about $10.8 billion. Those figures give the company room to pay the dividend, service debt and fund research while integrating the new acquisition.

Management said it remains on track to bring net leverage down to about two times earnings before interest, taxes, Depreciation and amortization within two to three years after the Apogee closing. That timeline implies debt repayment will compete with new deals for available cash, and it is consistent with the statement that further acquisitions will be modest in size and focused on immunology, neuroscience, oncology and obesity.

Why does the Medicare price negotiation ruling matter?

Under the Inflation Reduction Act, the government can negotiate prices for certain high-spending drugs covered by Medicare. Imbruvica, one of AbbVie's products, is already affected, and the decline in its sales this quarter was attributed partly to those pricing rules. A separate dispute concerned whether Botox, which has a large therapeutic business, qualified for negotiation.

Coverage of the call said a federal court ruled in the company's favour on that question, although the government may appeal. Until the process is finished, the matter remains a legal uncertainty rather than a settled outcome, and the company has not changed its guidance on the basis of it.

What is the company saying about obesity and other new areas?

Executives listed obesity among the areas in which they expect to look for bolt-on additions, alongside immunology, neuroscience and oncology. The company has been building a presence in obesity through partnerships and licensing agreements, and it has said it prefers to add early programmes rather than acquire a large commercial franchise.

No obesity product from AbbVie is on the market, and the quarter's financial figures include no revenue from the area. The remarks should therefore be read as a statement of intent about business development rather than as evidence of near-term sales, and they will be tested as further deals are announced. Until then, the company's discussion of the area is limited to general descriptions of the kinds of programmes it finds attractive, such as early-stage mid-sized transactions that fit existing research strengths.

How do the Vraylar and Botox numbers fit the neuroscience story?

Vraylar and Botox Therapeutic each generated a little over $1 billion in the quarter, with Vraylar growing at a low double-digit pace and Botox Therapeutic at a high single-digit pace. Both are mature products by pharmaceutical standards, yet they continue to expand as prescriptions rise and the labelled uses broaden.

The migraine products, Ubrelvy and Qulipta, grew faster, at roughly 20-7 and 38%, respectively, according to coverage of the call. This mix gives the neuroscience unit a foundation of established brands plus newer launches, and it gives management a reason to raise the full-year neuroscience revenue estimate by about $300 million.

Where does AbbVie fit in the wider market?

AbbVie is a large member of the S&P 500 and one of the best-known dividend payers among drug makers. The quarter's results will be compared with those of peers such as Merck, Pfizer and Bristol Myers Squibb, which are each managing their own patent expirations.

It is meant to inform, not to guide any decision, and it expresses no view on what the shares may do. Subsequent company announcements, conference presentations and regulatory decisions will Fill in the details that this early report cannot yet provide, particularly on launch timing for the newly approved medicines and on integration of the acquired antibody programmes.